NCT07121322View on ClinicalTrials.gov

Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2028

Conditions
Refractory Germ Cell TumorsDornase Alfa
Interventions
DRUG

dornase alfa i.v. and cisplatin

Cisplatin 100mg/m2 day 1, every 3 weeks, Dornase alfa 125 microgram/kg day 1-5 i.v. push over 30 seconds±5 seconds

Trial Locations (1)

83101

RECRUITING

National Cancer Institute, Bratislava

All Listed Sponsors
lead

National Cancer Institute, Slovakia

OTHER_GOV

NCT07121322 - Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer. | Biotech Hunter | Biotech Hunter